TRAIL Antibody (RIK-2): sc-56246
- TRAIL Antibody (RIK-2) is a mouse monoclonal IgG1 κ, cited in 7 publications, provided at 200 µg/ml
- raised against TRAIL of mouse origin
- recommended for detection of TRAIL of human origin by FCM
- available conjugated to either phycoerythrin or FITC for IF, IHC(P) and FCM
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for TRAIL Antibody (RIK-2). This work is in progress.
QUICK LINKS
SEE ALSO...
TRAIL Antibody (RIK-2) is a mouse monoclonal IgG1 antibody that detects TRAIL in human samples through flow cytometry (FCM). TRAIL, or TNF-related apoptosis-inducing ligand, plays a crucial role in regulating apoptosis, which is the process of programmed cell death essential for maintaining cellular homeostasis and immune system function. anti-TRAIL antibody (RIK-2) selectively induces apoptosis in cancer cells while sparing normal cells, making TRAIL a potential target for cancer immunotherapy. TRAIL functions by binding to its specific receptors, leading to the activation of apoptotic signaling pathways, which can trigger cell death in tumor cells. The targeted apoptosis-inducing properties of TRAIL highlight its importance in therapeutic strategies aimed at eliminating malignant cells without harming healthy tissue. TRAIL monoclonal antibody (RIK-2) is an invaluable tool for researchers studying the mechanisms of apoptosis and the potential therapeutic applications of TRAIL in cancer treatment.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
TRAIL Antibody (RIK-2) References:
- TNF-related apoptosis-inducing ligand death pathway-mediated human beta-cell destruction. | Ou, D., et al. 2002. Diabetologia. 45: 1678-88. PMID: 12488957
- TNF-related apoptosis-inducing ligand (TRAIL): a potential candidate for combined treatment of hematological malignancies. | Secchiero, P., et al. 2004. Curr Pharm Des. 10: 3673-81. PMID: 15579063
- The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway. | Wang, S. 2008. Oncogene. 27: 6207-15. PMID: 18931688
- TNF related apoptosis-inducing ligand and its receptors in ocular tumors. | Ning, Q., et al. 2011. Int J Ophthalmol. 4: 552-7. PMID: 22553720
- TNF-related apoptosis-inducing ligand promotes human preadipocyte proliferation via ERK1/2 activation. | Funcke, JB., et al. 2015. FASEB J. 29: 3065-75. PMID: 25857555
- TNF-related apoptosis-inducing ligand and cardiovascular disease in rheumatoid arthritis. | Dessein, PH., et al. 2015. Clin Exp Rheumatol. 33: 491-7. PMID: 25962765
- The role of XIAP in resistance to TNF-related apoptosis-inducing ligand (TRAIL) in Leukemia. | Saraei, R., et al. 2018. Biomed Pharmacother. 107: 1010-1019. PMID: 30257312
- Assessment of Placental Extracellular Vesicles-Associated Fas Ligand and TNF-Related Apoptosis-Inducing Ligand in Pregnancies Complicated by Early and Late Onset Preeclampsia. | Ayala-Ramírez, P., et al. 2021. Front Physiol. 12: 708824. PMID: 34366896
- Unspecific CTL Killing Is Enhanced by High Glucose via TNF-Related Apoptosis-Inducing Ligand. | Yang, W., et al. 2022. Front Immunol. 13: 831680. PMID: 35265081
- Bacteriophage-based particles carrying the TNF-related apoptosis-inducing ligand (TRAIL) gene for targeted delivery in hepatocellular carcinoma. | Sittiju, P., et al. 2024. Nanoscale. 16: 6603-6617. PMID: 38470366
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
TRAIL Antibody (RIK-2) | sc-56246 | 200 µg/ml | $316.00 | |||
TRAIL Antibody (RIK-2) FITC | sc-56246 FITC | 200 µg/ml | $330.00 | |||
TRAIL Antibody (RIK-2) PE | sc-56246 PE | 200 µg/ml | $343.00 |